Collaboration - October 2, 2013
Medicon Village and Sherbrook Innopole sign cooperation agreement
Medicon Village in Sweden and Sherbrooke Innopole in Canada have announced the ratification of a memorandum of understanding to stimulate cooperation among the life sciences hubs in their respective regions. The agreement was signed as part of the International Life Sciences Summit currently taking place in Sherbrooke. It will bring the two organizations together to […]
Collaboration - September 29, 2013
Gubra and Sanofi enter research collaboration
Gubra have announced the launch of a new research collaboration agreement with Sanofi focusing on the discovery of gut peptides. The new research program initiated between Gubra and Sanofi builds upon the established research consortium between Gubra, Gentofte Hospital and the University of Copenhagen partly funded by the Danish National Advanced Technology foundation. “We are […]
Collaboration - September 24, 2013
Karo Bio enters research collaboration
Karo Bio and 4D Science enters research collaboration on fibrotic diseases. The two companies will develop novel treatments for fibrotic diseases, based on a recent discoveries made by Dr. Jörg Distler. His research group has recently discovered that a specific nuclear receptor plays a key role in the pathogenesis of fibrotic diseases. The findings may […]
Collaboration - September 19, 2013
Medivir and Ferrer enter agreement
The two companies have entered an agreement for commercializing a new treatment for agitation associated with schizophrenia and bipolar diseases. The license and distribution agreement concerns commercialization of ADASUVE in the Nordic region. In Europe ADASUVE is approved for the treatment of mild to moderate agitation of patients with schizophrenia or bipolar disease. Under the […]
Collaboration - September 17, 2013
Camurus receives option-exercise milestone for CAM2029
Novartis has exercised its option to acquire an exclusive license for the further development and worldwide commercialization of CAM2029 for treatment of patients with acromegaly and neuroendocrine tumors (NETs). The license also covers additional future products based on the Camurus’ FluidCrystal Injection depot technology. The option exercise triggers an undisclosed milestone payment to Camurus from […]
Collaboration - September 17, 2013
AstraZeneca pays $50 million for rights to Merck cancer drug
Merck & Co has licensed its experimental cancer drug to AstraZeneca for a $50 million upfront fee. Under the terms of agreement Merck will also be eligible to receive future payments related to development and regulatory milestones as well as tiered royalties. The drug called MK-1775 is currently in mid-stage trials in combination with standard-of-care […]
